Inoxgen

Nitric Oxide, the active ingredient in Inoxgen, is a vasodilator presented as an inhalation gas for inhalation use. It treats pulmonary hypertension, neonatal respiratory distress syndrome, and acute respiratory failure in appropriate patient populations.

GNH USA supplies Inoxgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Inoxgen acts on the pulmonary vascular system to provide selective vasodilation in several serious respiratory conditions.

Pulmonary hypertension: reduces pulmonary arterial pressure and improves exercise capacity. Neonatal respiratory distress syndrome: facilitates pulmonary vasodilation to improve oxygenation in newborns. Acute respiratory failure: provides selective pulmonary vasodilation to support gas exchange.

Inoxgen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Cough: mild airway irritation during inhalation. - Flushing: transient warmth and redness of the skin. - Headache: mild to moderate headache episodes. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Hypotension: significant drop in systemic blood pressure. - Methemoglobinemia: rare oxidation of hemoglobin impairing oxygen transport. - Pulmonary edema: accumulation of fluid in the lungs, potentially life‑threatening.

When using Inoxgen, clinicians should observe several safety measures.

Monitor blood pressure: watch for systemic hypotension. Assess oxygenation: ensure adequate arterial oxygen levels. Avoid use in severe anemia: increased risk of methemoglobinemia. Use caution in pregnancy: insufficient safety data available. Do not combine with other potent pulmonary vasodilators without supervision. Store at ambient temperature: keep container sealed, protect from moisture and direct sunlight.

Inoxgen can interact with other medications that affect vascular tone or cGMP pathways.

Major Interactions (Avoid): - Concurrent use with other pulmonary vasodilators (e.g., sildenafil): risk of severe hypotension. - Co‑administration with nitric oxide donors (e.g., nitroglycerin): additive vasodilatory effect. - Use with methylene blue: antagonizes nitric oxide activity.

Moderate Interactions (Monitor Closely): - Combination with anticoagulants: monitor for increased bleeding. - Use with inhaled anesthetics: may enhance respiratory depression. - Interaction with drugs affecting cGMP metabolism (e.g., riociguat): monitor clinical response.